secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0000950170-25-043166
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 7.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health FY2024 net loss narrows to $5.7M; secures $25M equity line, in-licenses Entolimod
--------------------------------------------------------------------------------

- FY2024 revenue $0.8M (down from $1.2M); net loss -$5.7M vs -$8.2M in 2023 (30% decrease).
- Entered $25M equity purchase agreement with Mast Hill Fund; issued 29,800 commitment shares.
- In-licensed late-stage TLR5 agonist Entolimod from Statera Biopharma for acute radiation syndrome (Phase III).
- Appointed Michael Handley as COO and President of Tivic Biopharma; Lisa Wolf as interim CFO.
- ncVNS optimization study completed enrollment; disease-specific trials planned in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025043166/0000950170-25-043166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025043166/tivc-20250318.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-043166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer